Immune checkpoint therapy of mesothelioma: Pre-clinical bases and clinical evidences

Cytokine & Growth Factor Reviews 2017 July 12 [Epub ahead of print] [Link]

Calabrò L, Ceresoli GL, D’Incecco A, Scherpereel A, Aerts J, Maio M


Treatment with immune-checkpoint blocking monoclonal antibody (mAb) is demonstrating a significant efficacy in different tumor types. Here, we discuss the impact of this promising approach in malignant mesothelioma (MM), a still dreadful disease in which medical treatment has been set on platinum based chemotherapy for decades with unsatisfactory results.